Antineoplastic Agents, Immunological
"Antineoplastic Agents, Immunological" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antineoplastic agents containing immunological agents (e.g. MAbs). These pharmacologic preparations inhibit or prevent the proliferation of NEOPLASMS.
| Descriptor ID |
D000074322
|
| MeSH Number(s) |
D27.505.954.248.384
|
| Concept/Terms |
Antineoplastics, Monoclonal Antibodies- Antineoplastics, Monoclonal Antibodies
- Antibodies Antineoplastics, Monoclonal
- Monoclonal Antibodies Antineoplastics
- Monoclonal Antibodies, Antineoplastic
- Antineoplastic Monoclonal Antibodies
- Antineoplastic MAbs
- Antineoplastics, Monoclonal Antibody
- Monoclonal Antibody Antineoplastics
- MAbs, Antineoplastic
|
Below are MeSH descriptors whose meaning is more general than "Antineoplastic Agents, Immunological".
Below are MeSH descriptors whose meaning is more specific than "Antineoplastic Agents, Immunological".
This graph shows the total number of publications written about "Antineoplastic Agents, Immunological" by people in this website by year, and whether "Antineoplastic Agents, Immunological" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2015 | 1 | 0 | 1 |
| 2016 | 10 | 8 | 18 |
| 2017 | 39 | 11 | 50 |
| 2018 | 77 | 28 | 105 |
| 2019 | 94 | 29 | 123 |
| 2020 | 71 | 36 | 107 |
| 2021 | 38 | 15 | 53 |
| 2022 | 24 | 4 | 28 |
| 2023 | 13 | 1 | 14 |
| 2024 | 2 | 28 | 30 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antineoplastic Agents, Immunological" by people in Profiles.
-
Efficacy of Trastuzumab Deruxtecan in HER2-Expressing Solid Tumors by Enrollment HER2 IHC Status: Post Hoc Analysis of DESTINY-PanTumor02. Adv Ther. 2024 Nov; 41(11):4125-4139.
-
Chromosomal instability is associated with prognosis and efficacy of bevacizumab after resection of colorectal cancer liver metastasis. Ann Med. 2024 Dec; 56(1):2396559.
-
Liver elastography for risk-assessment of liver toxicity and risk factors for Sinusoidal obstruction syndrome in patients with acute lymphoblastic leukemia receiving inotuzumab ozogamicin. Blood Cancer J. 2024 08 07; 14(1):129.
-
Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial. Lancet Oncol. 2024 Sep; 25(9):1147-1162.
-
Airway Injury Related to Radiation Treatment and Durvalumab Treatment: A Case Series. J Bronchology Interv Pulmonol. 2024 Oct 01; 31(4).
-
Inotuzumab ozogamicin in adult acute lymphoblastic leukemia: Development, current status, and future directions. Cancer. 2024 Nov 01; 130(21):3631-3646.
-
Targeting undruggable phosphatase overcomes trastuzumab resistance by inhibiting multi-oncogenic kinases. Drug Resist Updat. 2024 Sep; 76:101118.
-
Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL. Blood. 2024 07 04; 144(1):61-73.
-
Clinical Validation of Mathematically Derived Early Tumor Dynamics for Solid Tumors in Response to Durvalumab. JCO Clin Cancer Inform. 2024 Jul; 8:e2300254.
-
Matching-adjusted indirect comparison from the Lymphoma Epidemiology of Outcomes Consortium for Real World Evidence (LEO CReWE) study to a clinical trial of mosunetuzumab in relapsed or refractory follicular lymphoma. Haematologica. 2024 07 01; 109(7):2177-2185.